Linmiao Jiang

Apr 27, 2024 | nature.com | Luca Fischer |Linmiao Jiang |Stephan Stilgenbauer |Ullrich Graeven |Jochen Greiner |Eric Durot | +3 more

AbstractThe therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT).